IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

The Case–Control Study Of Prevalence Of Anaemia Among Patients With Type 2 Diabetes Mellitus

Melam.Yesuratnam[1], AbbireddyArunkumar[2], Chintala.Powerdurgesh[3],

Monapati.Charan kumar[4], Thanugundala.Anilkumar[5]

[1,]Assistant Professor, Department of Pharmacy Practice, A.M Reddy Memorial college of Pharmacy, Petlurivaripalem, NarasaraoPeta, Palnadu dist, Pin: 522601, A.P.

[2.,4,5,]B. Pharm Students , A.M Reddy Memorial College of Pharmacy, Petlurivararipalem, Narasaraopet, Palnadu-522601, Andhra Pradesh.

[3,]Pharm-D Student, A.M Reddy Memorial College of Pharmacy, Petlurivararipalem, Narasaraopet, Palnadu-522601, Andhra Pradesh

ABSTRACT:-

Anemia is a common and often overlooked complication in patients with type 2 diabetes mellitus (T2DM). Th is condition can significantly impact patients' quality of life and increase the risk of diabetesrelated complications. The prevalence of anemia in T2DM patients varies widely, influenced by fact ors such as age, gender, glycemic control, duration of diabetes, and the presence of comorbid conditions like c hronic kidney disease.

Recent research focuses on understanding the pathophysiology of anemia in T2DM, including the roles of chr onic inflammation, oxidative stress, and iron metabolism. Novel therapies and personalized medicine approac hes are being explored to improve the management of anemia in this population. Healthcare policy implicatio ns are also being considered to ensure early detection and effective treatment of anemia in T2DM patients, the reby enhancing overall diabetes management and patient outcomes.

This study highlights the importance of comprehensive anemia screening and management in T2DM patients t o mitigate the adverse effects of anemia and improve their quality of life. Future research directions include in vestigating the underlying mechanisms, developing new treatments, and integrating personalized medicine ap proaches to tailor therapy to individual patient needs.

Keywords:- Hemoglobin concentration, Anemia, Renal insufficiency, Diabetes

INTRODUCTION:

Type 2 Diabetes Mellitus, or T2DM, is a complex metabolic disorder that has changed the lives of millions around the globe with far-reaching consequences on cardiovascular health, kidney functions, and overall well-being. More and more frequently diagnosed as the number one cause of the growing incidence of T2DM world-wide, healthcare providers face the daunting task of controlling elevated blood sugars and a myriad of associated comorbid conditions in patients. Of these, anemia stands out as often overlooked yet equally important in patient outcomes.

Common comorbidity in T2DM patients, anemia is marked by low levels of hemoglobin, affecting about 17.5% to 21.4% of this population. The perfect storm of anemia and T2DM heightens cardiovascular risk, compromises quality of life, and increases healthcare costs. Despite its prevalence and consequences, anemia in T2DM remains underdiagnosed and undertreated.

This knowledge gap has relevant implications on the care of patients and underscores the need to heighten awareness, improve screening strategies, and implement evidence-based management protocols. For healthcare providers, an appreciation of the prevalence, causes, consequences, and implications of anemia in T2DM will better inform them about complexities of this comorbidity and help them develop appropriate strategies for the improvement of patient outcomes.

Prevalence of Anemia in T2DM:-

Recent case-control studies indicate a significantly higher prevalence of anemia among individuals with T2DM compared to non-diabetic controls. Various studies report prevalence rates ranging from 20% to 50%, depending on the population and diagnostic criteria used. Factors such as age, sex, duration of diabetes, and glycemic control levels contribute to this variability.

Objective:

1. To determine the prevalence of anemia among patients with T2DM.

2. To compare the prevalence of anemia between patients with T2DM (cases) and those without T2DM (controls).

3. To identify potential risk factors for anemia in patients with T2DM.

Epidemiology :-

Anemia is a frequent complication in patients with type 2 diabetes mellitus (T2DM), impacting their overall h ealth and quality of life. A case-
control study aims to identify the prevalence and risk factors associated with anemia in this population. By co mparing T2DM patients with and without anemia, researchers can better

understand the contributing factors and develop targeted interventions.

PATHOPHYSIOLOGY:-

The interaction between T2DM and anemia involves several mechanisms. Insulin resistance can lead to increased hepcidin levels, which inhibit iron absorption and release from stores, ultimately contributing to functional iron deficiency. Moreover, inflammation associated with diabetes can further disrupt erythropoiesis.



Methodology :-

A case-control study on anemia in T2DM typically involves the following steps:

1)Study Population:

Cases: Patients with T2DM and diagnosed anemia.

Controls: Patients with T2DM but without anemia.

2)Selection Criteria:

Inclusion Criteria: Define criteria for selecting cases and controls, such as age range, duration of diabetes, an d absence of other major illnesses.

Exclusion Criteria: Exclude patients with conditions that could independently cause anemia, such as other ch ronic diseases or recent blood loss.

3)Data Collection:

Medical Records: Collect data from medical records, including hemoglobin levels, HbA1c, kidney function t ests, and other relevant parameters.

Questionnaires: Administer questionnaires to gather information on lifestyle factors, dietary habits, medicati on use, and other potential risk factors.

4)Matching:

Match Cases and Controls: Match cases and controls on variables like age, gender, and duration of diabetes to reduce confounding factors.

5)Statistical Analysis:

Descriptive Statistics: Summarize the data using means, medians, and proportions.

Comparative Analysis: Use statistical tests (e.g., chi-square, t-
tests) to compare the prevalence of risk factors between cases and controls.

Multivariate Analysis: Perform logistic regression to identify independent risk factors for anemia in T2DM p atients.

6)Ethical Considerations:

Informed Consent: Ensure all participants provide informed consent.

Confidentiality: Maintain the confidentiality of patient data.

Risk factors:-

1)Older Age: Anemia is more common in older adults with T2DM2.

2)Female Gender: Women with T2DM are at a higher risk of developing anemia compared to men.

3)Poor Glycemic Control: High blood sugar levels can contribute to the development of anemia.

4)Long Duration of Diabetes: Patients with T2DM for more than 5 years are at increased risk.

5)Diabetic Nephropathy: Kidney disease related to diabetes can lead to anemia.

6)Retinopathy and Neuropathy: Complications of diabetes affecting the eyes and nerves can be associated with anemia.

7)Chronic Kidney Disease (CKD): Advanced stages of CKD (stage 3 or higher) are linked to anemia.

8)Ischemic Heart Disease (IHD): Heart disease in diabetic patients can contribute to anemia

9)Peripheral Vascular Disease (PVD): Poor circulation in the limbs can be a factor.

10)Diabetic Foot Ulcers (DFU): Ulcers and infections in the feet can lead to anemia

11)Use of Aspirin: Regular use of aspirin can affect blood cell production.

Management and Treatment:-

1)Identify the Cause of Anemia:

Nutritional Deficiencies: Ensure adequate intake of iron, vitamin B12, and folate through diet or supplements.

Chronic Diseases: Manage underlying conditions like chronic kidney disease or gastrointesti-
nal bleeding that may contribute to anemia.

2)Optimize Diabetes Management:-

Glycemic Control: Maintain blood glucose levels within target ranges to prevent complications that can exace rbate anemia.

Monitor Hemoglobin A1c (HbA1c): Regularly check HbA1c levels to assess long-term glucose control.

3)Medications:-

Iron Supplements: Prescribe oral or intravenous iron supplements if iron deficiency is identified.

Erythropoiesis:-
4)Stimulating Agents (ESAs): Consider ESAs for patients with anemia due to chronic kidney disease.

Blood Transfusions**:** In severe cases, blood transfusions may be necessary.

5)Lifestyle Modifications:

Encourage a balanced diet rich in iron, vitamin B12, and folate.

Exercise: Regular physical activity can improve overall health and help manage both diabetes and anemia.

6)Regular Monitoring:

Blood Tests: Regularly monitor complete blood count (CBC), iron levels, and other relevant paramers.

Follow-Up: Schedule regular follow-
up appointments to assess the effectiveness of treatment and make necessary adjustments.

Treatment Goals

*Eliminate Symptoms***:** Address symptoms like fatigue, weakness, and shortness of breath.

*Prevent Complications***:** Prevent complications associated with both anemia and diabetes, such as cardiovascul ar issues and neuropathy.

*Improve Quality of Life***:** Enhance the patient's overall well-being and quality of life.

Current Research and Future Directions:-

1.Investigating Anemia's Pathophysiology in T2DM:

Research is honing in on the intricate mechanisms behind anemia in T2DM, exploring how chronic inflammat ion, oxidative stress, and iron regulation (via hepcidin) play roles. Unraveling these details paves the way for t argeted treatment approaches.

2.Novel Therapies for Anemia in T2DM:

Cutting-edge treatments are being explored, from advanced erythropoiesis-
stimulating agents (ESAs) to innovative oral iron supplements. These aim to improve anemia management wh ile minimizing side effects and enhancing patient comfort.

3.Personalized Medicine Approaches:

Personalized medicine is a growing field, with research focusing on tailoring treatments based on genetic prof iles. This approach aims to maximize treatment effectiveness and reduce adverse effects, providing more indiv idualized care.

4.Healthcare Policy Implications for Anemia Management in T2DM:

Efforts are underway to shape policies that enhance anemia management in T2DM patients. This includes pro moting early detection, ensuring access to effective treatments, and integrating anemia management into broa der diabetes care protocols.

These research directions and developments are set to improve the quality of life for patients battling both T2 DM and anemia.

Diagnosis and Screening:-

1)Hemoglobin A1c and Anemia Diagnosis in T2DM:

Hemoglobin A1c (HbA1c): This test measures average blood glucose levels over the past 2-3 months. While primarily used to monitor diabetes control, HbA1c can be affected by anemia, particularly ir on deficiency anemia, leading to falsely elevated results.

*Screening Strategies for Anemia in T2DM Patients:

2)Routine Blood Tests: Regular complete blood count (CBC) tests can help detect anemia early. Monitoring h emoglobin levels, mean corpuscular volume (MCV), and red cell distribution width (RDW) are crucial.

*Risk Factor Assessment: Identifying patients at higher risk, such as those with chronic kidney disease, older age, or poor glycemic control, can help target screening efforts more effectivel-y.

3.Role of Biomarkers in Anemia Detection:

*Serum Ferritin: A key biomarker for iron status, low serum ferritin levels indicate iron deficiency anemia3.

*Tansferrin Saturation: This test measures the amount of iron bound to transferrin in the blood, helping to dia gnose iron deficiency.

*Vitamin B12 and Folate Levels: Deficiencies in these vitamins can cause anemia, so measuring their levels is important for accurate diagnosis.

Current Research and Future Directions:-

1)Investigating Anemia's Pathophysiology in T2DM:

*Researchers are delving into the intricate mechanisms behind anemia in T2DM, exploring how chronic infla mmation, oxidative stress, and iron regulation (via hepcidin) play roles. Unraveling these details paves the wa y for targeted treatment approaches.

2)Novel Therapies for Anemia in T2DM:

*Cutting-edge treatments are being explored, from advanced erythropoiesis-stimulating agents (ESAs) to innovative oral iron supplements. These aim to improve anemia management wh ile minimizing side effects and enhancing patient comfort.

3)Personalized Medicine Approaches:

*Personalized medicine is a growing field, with research focusing on tailoring treatments based on genetic pro files. This approach aims to maximize treatment effectiveness and reduce adverse effects, providing more indi vidualized care.

4)Healthcare Policy Implications for Anemia Management in T2DM:

*Efforts are underway to shape policies that enhance anemia management in T2M patients. This includes pro moting early detection, ensuring access to effective treatments, and integrating anemia management into broa der diabetes care protocols.

Conclusion

Anemia is a significant and prevalent complication among patients with type 2 diabetes mellitus (T2DM). Its presence exacerbates the challenges faced by these patients, affecting their overall health and quality of life. T he higher prevalence of anemia in T2DM can be attributed to factors such as poor glycemic control, chronic ki dney disease, and prolonged duration of dia-betes.

Current research is deepening our understanding of the pathophysiology of anemia in T2DM, uncovering the r oles of chronic inflammation, oxidative stress, and disrupted iron metabolism. Novel therapeutic approaches, i ncluding advanced erythropoiesis-
stimulating agents and personalized medicine strategies, hold promise for more effective management of ane mia in this population.

Efforts to improve screening and diagnosis, along with targeted treatment plans, are essential. Healthcare poli cies should prioritize integrated care approaches to ensure early detection and comprehensive management of anemia in T2DM patients. By addressing anemia alongside diabetes, healthcare providers can significantly en hance patient outcomes and quality of life.

REFERENCES:-

1) Thomas, M. C., et al. (2013). Anemia in patients with type 2 diabetes: prevalence, diagnosis, and treatment. Diabetes/Metabolism Research and Reviews, 29(5), 377-385. DOI: 10.1002/dmrr.241
2) Singh, D. K., et al. (2019). Prevalence and correlates of anemia in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Journal of Clinical Epidemiology, 115, 137-146. DOI: 10.1016/j.jclinepi.2019.05.004
3) Lipscombe, L. L., et al. (2018). Anemia and cardiovascular disease in diabetes. Diabetes/Metabolism Research and Reviews, 34(3), e2975. DOI: 10.1002/dmrr.2975
4) - Thomas, M. C., et al. (2013). Anemia in type 2 diabetes: Association with kidney disease and cardiovascular risk. Journal of Clinical Endocrinology and Metabolism, 98(11), 4325-4332. DOI: 10.1210/jc.2013-2104
5) - Lipscombe, L. L., et al. (2018). Anemia and cardiovascular disease in diabetes. Cardiovascular Diabetology, 17(1), 1-9. DOI: 10.1186/s12933-018-0744-4
6) - Martinez, R., et al. (2019). Treatment of anemia in patients with type 2 diabetes: A systematic review. Diabetes Research and Clinical Practice, 157, 107927. DOI: 10.1016/j.diabres.2019.107927
7) Porta MGD, Malcovati L. Myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 2011;96:180–3. doi: 10.3324/haematol.2010.039875. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8) Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351–62. doi: 10.1111/j.1365-2141.2007.06807.x. [PubMed] [CrossRef] [Google Scholar]
9) Ida H. Pathogenesis and clinical examination of autoinflammatory syndrome. Rinsho Byori. 2015;63(10):1207–12. [PubMed] [Google Scholar]
10) . Wilson J, Yao G, Rafferty J, et al. A systematic review and economic evaluation of epoetin alpha epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1–202. doi: 10.3310/hta11130. [PubMed] [CrossRef] [Google Scholar]
11) . Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Anemia induced by solid tumor chemotherapy. Recenti Prog Med. 2002;93(11):585–601. [PubMed] [Google Scholar]

12). Jager U, Lechner K, et al. Autoimmune hemolytic anemia. In: Hoffman R, Benz EJ Jr, Silberstein LE, et al., editors. Hematology: basic principles and practice. 6. Philadelphia: Elsevier Saunders; 2012. [Google Scholar]
13). Price EA, Schrier SS, et al. Extrinsic nonimmune hemolytic anemias. In: Hoffman R, Benz EJ Jr, Silberstein LE, et al., editors. Hematology: basic principles and practice. 6. Philadelphia: Elsevier Saunders; 2012. [Google Scholar]
14). Gallagher PG. The red blood cell membrane and its disorders: hereditary spherocytosis, elliptocytosis, and related diseases. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT, editors. William's hematology. 8. New York: McGraw Hill; 2010. pp. 617–46. [Google Scholar]
15). Lichtman MA. Hemolytic anemia due to infections with microorganisms. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT, editors. William's hematology. 8. New York: McGraw Hill; 2010. pp. 769–76. [Google Scholar]
16). Beutler E, Bull BS, Herrmann PC. Hemolytic anemia resulting from chemical and physical agents. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT, editors. William's hematology. 8. New York: McGraw Hill; 2010. pp. 763–68. [Google Scholar]
17) Glader BE. Hemolytic anemia in children. Clin Lab Med. 1999;19(1):87–111. [PubMed] [Google Scholar]
18) Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66(4):1596–605. doi: 10.1111/j.1523-1755.2004.00925.x. [PubMed] [CrossRef] [Google Scholar]
19) Cusick M, Chew EY, Hoogwerf B, Agron E, Wu L, Lindley A, et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS). Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int. 2004;66(3):1173–9. doi: 10.1111/j.1523-1755.2004.00869.x. [PubMed] [CrossRef] [Google Scholar]
20) Hahn U. Classification of anaemia. IMVS Newsletter. 2007;65:8–10. [Google Scholar]
21) Adejumo BI, Dimkpa U, Ewenighi CO, Onifade AA, Mokogwu AT, Erhabor TA, et al. Incidence and risk of anemia in type-2 diabetic patients in the absence of renal impairment. Health. 2012;4(6):304–8. doi: 10.4236/health.2012.46050. [CrossRef] [Google Scholar]
22) Bonakdaran S, Gharebaghi M, Vahedian M. Prevalence of anemia in type-2 diabetes and role of renal involvement. Saudi J Kidney Dis Transpl. 2011;22:286–90. [PubMed] [Google Scholar]
23). Feteh VF, Choukem SP, Kengne AP, Nebongo DN, Ngowe-Ngowe M. Anemia in type 2 diabetic patients and correlation with kidney function in a tertiary care sub-Saharan African hospital: a cross-sectional study. BMC Nephrol. 2016;17(1):29. doi: 10.1186/s12882-016-0247-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24) Ishimura E, Nishizawa Y, Okuno S, Matsumoto N, Emoto M, Inaba M, et al. Diabetes mellitus increases the severity of anaemia in non-dialysed patients with renal failure. J Nephrol. 1998;11(2):83–6. [PubMed] [Google Scholar]
25) Dikow R, Schwenger V, Schomig M, Ritz E. How should we manage anaemia in patients with diabetes? Nephrol Dial Transplant. 2002;17(Suppl 1):67–72. doi: 10.1093/ndt/17.suppl_1.67. [PubMed] [CrossRef] [Google Scholar]
26) Yun YS, Lee HC, Yoo NC, Song YD, Lim SK, Kim KR, et al. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract. 1999;46(3):223–9. doi: 10.1016/S0168-8227(99)00097-2. [PubMed] [CrossRef] [Google Scholar]

27) Kojima K, Totsuka Y. Anemia due to reduced serum erythropoietin concentration in non-uremic diabetic patients. Diabetes Res Clin Pract. 1995;27(Suppl):229–33. doi: 10.1016/0168-8227(95)01042-C. [PubMed] [CrossRef] [Google Scholar]

28). Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ. Erythropoietin depletion and anemia in diabetes mellitus. Diabet Med. 1999;16(10):813–19. doi: 10.1046/j.1464-5491.1999.00172.x. [PubMed] [CrossRef] [Google Scholar]

29). Stevens PE, O'Donoghue DJ, Lameire NR. Anaemia in patients with diabetes: unrecognised, undetected and untreated? Curr Med Res Opin. 2003;19(5):395–401. doi: 10.1185/030079903125002036. [PubMed] [CrossRef] [Google Scholar]

30) National Kidney Foundation K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis. 2001;37:S182–238. doi: 10.1016/S0272-6386(01)70008-X. [PubMed] [CrossRef] [Google Scholar]

31) McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501–10. doi: 10.1185/030079904X2763. [PubMed] [CrossRef] [Google Scholar]

32) Valderrabano F. Anaemia management in chronic kidney disease patients: an overview of current clinical practice. Nephrol Dial Transplant. 2002;17:13–8. doi: 10.1093/ndt/17.suppl_1.13. [PubMed] [CrossRef] [Google Scholar]

33). Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care. 2003;26:4 1164–9. [PubMed] [Google Scholar]

34). Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int. 2002;61(Suppl 80):35–8. doi: 10.1046/j.1523-1755.61.s80.7.x. [PubMed] [CrossRef] [Google Scholar]

35) Tudor-Locke CE, Bell RC, Meyers AM. Revisiting the role of physical activity and exercise in the treatment of type 2 diabetes. Can J Appl Physiol. 2000;25:466–9. doi: 10.1139/h00-031. [PubMed] [CrossRef] [Google Scholar]

36)Ayisi J, van Eijk AM, Ter Kuile F, et al. Risk factors for HIV infection among pregnant women attending an antenatal clinic in Western Kenya. Intl J STD AIDS. 2000;11:393–401. doi: 10.1258/0956462001916119. [PubMed] [CrossRef] [Google Scholar